Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$4.32
$0.04(0.93%)
At close: 4:00 PM EDT
$4.32
$0.04(0.93%)
Day’s Range― - ―
52-Week Range$3.86 - $10.08
Previous Close$4.39
Volume459.78K
Average Volume (3M)1.27M
Market Cap
$342.90M
Enterprise Value$176.57
Total Cash (Recent Filing)$149.90M
Total Debt (Recent Filing)$3.63M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 05, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding64,697,400
10 Day Avg. Volume807,675
30 Day Avg. Volume1,267,347
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.60Price Target Upside237.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Atebimetinib EfficacyThe observed efficacy supports atebimetinib’s potential differentiation in pancreatic cancer. If confirmed in controlled trials, these results could underpin a durable commercial opportunity and strengthen the company’s oncology platform.
Pipeline AdvancementProgress across late-stage and earlier programs broadens the pipeline beyond one asset. Multiple development opportunities can improve long-term value creation and reduce dependence on a single clinical outcome.
Low Financial LeverageVery low leverage limits mandatory financing costs and reduces balance-sheet risk during clinical development. Substantial equity provides a cushion for operations, although continued losses may erode that support.
Bears Say
No Durable Product RevenueThe absence of recurring commercial revenue leaves Immuneering dependent on clinical success, partnerships or capital markets. This limits earnings visibility and makes future funding capacity central to the business model.
Persistent Cash BurnContinued cash consumption is inherent to the company’s development model and must be funded before products generate revenue. Persistent burn can require additional financing, potentially weakening financial flexibility and ownership.
Clinical Execution RiskThe lead program still requires confirmation in a pivotal trial, and cross-trial benchmarks cannot establish efficacy conclusively. A long development timeline leaves substantial regulatory, clinical and execution uncertainty.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $3.86 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $342.90M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on Aug 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.264 by -$0.006.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.3.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,697,400 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.264. Following the earnings report the stock price went down -0.227%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.60 (237.96% Upside)
$14.60 (237.96% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 88.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $36.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
404.43%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$14.60
▲(237.96% Upside)
Technical Analysis
Ownership Overview
9.38% Insiders
15.57% Mutual Funds
9.33% Other Institutional Investors
56.84% Public Companies and
Individual Investors